Document:

EX-10.19

 Exhibit 10.19 

CONSULTING AGREEMENT 
 This Consulting
Agreement (the “Agreement”) is made effective as of June 5, 2019 (the “Effective Date”), by and between Checkmate Pharmaceuticals Inc., a Delaware corporation, with its principal place of business being 101 Main St.; 14th Floor, Cambridge, MA 02142 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability corporation, with its principal place of business being 91 Middle Road,
Southborough, MA 01772 (“Danforth”). The Company and Danforth are herein sometimes referred to individually as a “Party” and collectively as the “Parties.” 

WHEREAS, the Company possesses know-how and proprietary technology in the field of CpG
oligonucleotides that it is using to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers; and 

WHEREAS, Danforth has expertise in financial and corporate operations and strategy; and 

WHEREAS, Danforth desires to serve as an independent consultant for the purpose of providing the Company with certain strategic and financial
advice and support services, as more fully described in Exhibit A attached hereto, (the “Services”); and 
 WHEREAS, the
Company wishes to engage Danforth on the terms and conditions set forth herein. 
 NOW THEREFORE, in consideration of the foregoing and for
other good and valuable consideration, the receipt of which are hereby acknowledged, the Parties agree and covenant as follows. 
  

	1.	 Services of Consultant. Danforth will assist the Company with matters relating to the Services. The
Services are more fully described in Exhibit A attached hereto. Danforth and the Company will review the Services on a monthly basis to prioritize and implement the tasks listed on Exhibit A. Danforth shall perform its duties and obligations under
this Agreement with the highest degree of professionalism. In Danforth’s professional capacity, Danforth believes that all employees assigned to perform work under this Agreement shall have a level of skill and experience commensurate with the
requirements of the task to which such employee is required to perform. 

  

	2.	 Compensation for Services. In full consideration of Danforth’s full, prompt and faithful
performance of the Services, the Company shall compensate Danforth a consulting fee more fully described in Exhibit A (the “Consulting Fee”). Danforth shall, from time to time, but not more frequently than twice per calendar month,
invoice the Company for Services rendered, and such invoice will be paid upon fifteen (15) days of receipt. Each month the Parties shall evaluate jointly the current fee structure and scope of Services. Danforth reserves the right to an
annual increase in consultant rates of up to 4%, effective January 1 of each year. Upon termination of this Agreement pursuant to Section 3, no compensation or benefits of any kind as described in this Section 2
shall be payable or issuable to Danforth after the effective date of such termination. In addition, the 

	 	
Company will reimburse Danforth for reasonable out-of-pocket business expenses, including but not limited to travel
and parking, incurred by Danforth in performing the Services hereunder, upon submission by Danforth of supporting documentation reasonably acceptable to the Company. Any such accrued expenses in any given three (3) month period that exceed one
thousand dollars ($1,000) shall be submitted to the Company for its prior written approval. 

 All Danforth invoices and
billing matters should be addressed to: 
  

					
	Company Accounts Payable Contact:	  	101 Main St., 14th Floor	  	
		  	Cambridge, MA 02142]	  	

 All Company payments and billing inquiries should be addressed to: 

 

					
	Danforth Accounting:	  	Danforth Advisors	  	
		  	PO Box 335	  	
		  	Southborough, MA 01772	  	

  

	3.	 Term and Termination. The term of this Agreement will commence on the Effective Date and will continue
through the anniversary of such date in the next calendar year (the “Term”). This Agreement may be extended for an additional period by mutual written agreement. This Agreement may be terminated by either Party hereto: (a) with
Cause (as defined below), upon thirty (30) days prior written notice to the other Party; or (b) without cause upon sixty (60) days prior written notice to the other Party. For purposes of this
Section 3, “Cause” shall include: (i) a breach of the terms of this Agreement which is not cured within thirty (30) days of written notice of such default or (ii) the commission of any act of
fraud, embezzlement or deliberate disregard of a rule or policy of the Company. 

  

	4.	 Time Commitment. Danforth will devote such time to perform the Services under this Agreement as may
reasonably be required. 

  

	5.	 Place of Performance. Danforth will perform the Services at such locations upon which the Company and
Danforth may mutually agree. Danforth will not, without the prior written consent of the Company, perform any of the Services at any facility or in any manner that might give anyone other than the Company any rights to or allow for disclosure of any
Confidential Information (as defined below). 

  

	6.	 Compliance with Policies and Guidelines. Danforth will perform the Services in accordance with all rules
or policies adopted by the Company that the Company discloses in writing to Danforth. 

	7.	 Confidential Information. Danforth acknowledges and agrees that during the course of performing the
Services, the Company may famish, disclose or make available to Danforth information, including, but not limited to, material, compilations, data, formulae, models, patent disclosures, procedures, processes, business plans, projections, protocols,
results of experimentation and testing, specifications, strategies and techniques, and all tangible and intangible embodiments thereof of any kind whatsoever (including, but not limited to, any apparatus, biological or chemical materials, animals,
cells, compositions, documents, drawings, machinery, patent applications, records and reports), which is owned or controlled by the Company and is marked or designated as confidential at the time of disclosure or is of a type that is customarily
considered to be confidential information (collectively the “Confidential Information”). Danforth acknowledges that the Confidential Information or any part thereof is the exclusive property of the Company and shall not be disclosed to any
third party without first obtaining the written consent of the Company. Danforth further agrees to take all practical steps to ensure that the Confidential Information, and any part thereof, shall not be disclosed or issued to its affiliates, agents
or employees, except on like terms of confidentiality. The above provisions of confidentiality shall apply for a period of five (5) years. 

  

	8.	 Intellectual Property. Danforth agrees that all ideas, inventions, discoveries, creations, manuscripts,
properties, innovations, improvements, know-how, inventions, designs, developments, apparatus, techniques, methods, and formulae that Danforth conceives, makes, develops or improves as a result of performing
the Services, whether or not reduced to practice and whether or not patentable, alone or in conjunction with any other party and whether or not at the request or upon the suggestion of the Company (all of the foregoing being hereinafter collectively
referred to as the “Inventions”), shall be the sole and exclusive property of the Company. Danforth hereby agrees in consideration of the Company’s agreement to engage Danforth and pay compensation for the Services rendered to the
Company and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged that Danforth shall not, without the prior written consent of the Company, directly or indirectly, consult for, or become an employee
of, any company which conducts business in the Field of Interest anywhere in the world. As used herein, the term “Field of Interest” shall mean the research, development, manufacture and/or sale of the products resulting from the
Company’s technology. The limitations on competition contained in this Section 8 shall continue during the time that Danforth performs any Services for the Company, and for a period of three (3) months following the termination
of any such Services that Danforth performs for the Company. If any part of this section should be determined by a court of competent jurisdiction to be unreasonable in duration, geographic area, or scope, then this Section 8 is intended
to and shall extend only for such period of time, in such area and with respect to such activity as is determined to be reasonable. Except as expressly provided herein, nothing in this Agreement shall preclude Danforth from consulting for or being
employed by any other person or entity. 

  

	9.	 Non Solicitation. All personnel representing Danforth are employees or contracted agents of Danforth.
Accordingly, they are not retainable as employees or contractors by the Company and the Company hereby agrees not to solicit, hire or retain their services for so 

	 	
long as they are employees or contracted agents of Danforth and for two (2) years thereafter. Should the Company violate this restriction, it agrees to pay Danforth liquidated damages equal
to thirty percent (30%) of the employee’s starting annual base salary and target annual bonus for each Danforth contracted agent hired by the Company in violation of this Agreement, plus Danforth’s reasonable attorneys’ fees and costs
incurred in enforcing this agreement should the Company fail or refuse to pay the liquidated damages amount in full within thirty (30) days following its violation. 

 

	10.	 Placement Services. In the event that Danforth refers a potential employee to the Company and that
individual is hired, Danforth shall receive a fee equal to twenty percent (20%) of the employee’s starting annual base salary and target annual bonus. This fee is due and owing whether an individual is hired, directly or indirectly on a
permanent basis or on a contract or consulting basis by the Company, as a result of Danforth’s efforts within one (1) year of the date applicant(s) are submitted to the Company. Such payment is due within thirty (30) days of
the employee’s start date. 

  

	11.	 No Implied Warranty. Except for any express warranties stated herein, the Services are provided on an
“as is” basis, and the Company disclaims any and all other warranties, conditions, or representations (express, implied, oral or written), relating to the Services or any part thereof. Further, in performing the Services Danforth is not
engaged to disclose illegal acts, including fraud or defalcations, which may have taken place. The foregoing notwithstanding, Danforth will promptly notify the Company if Danforth becomes aware of any such illegal acts during the performance of the
Services. Because the Services do not constitute an examination in accordance with standards established by the American Institute of Certified Public Accountants (the “AICPA”), Danforth is precluded from expressing an opinion as to
whether financial statements provided by the Company are in conformity with generally accepted accounting principles or any other standards or guidelines promulgated by the AICPA, or whether the underlying financial and other data provide a
reasonable basis for the statements. 

  

	12.	 Indemnification. Each Party hereto agrees to indemnify and hold the other Party hereto, its directors,
officers, agents and employees harmless against any claim based upon circumstances alleged to be inconsistent with such representations and/or warranties contained in this Agreement. Further, the Company shall indemnify and hold harmless Danforth
and any of its subcontractors against any claims, losses, damages or liabilities (or actions in respect thereof) that arise out of or are based on the Services performed hereunder, except for any such claims, losses, damages or liabilities arising
out of the gross negligence or willful misconduct of Danforth or any of its subcontractors. The Company will endeavor to add Consultant and any applicable subcontractor to its insurance policies as additional insureds. 

 

	13.	 Independent Contractor. Danforth is not, nor shall Danforth be deemed to be at any time during the term
of this Agreement, an employee of the Company, and therefore Danforth shall not be entitled to any benefits provided by the Company to its employees, if applicable. Danforth’s status and relationship with the Company shall be that of an
independent contractor and consultant. Danforth shall not state or imply, directly or indirectly, that Danforth is empowered to bind the Company without the Company’s 

	 	
prior written consent. Nothing herein shall create, expressly or by implication, a partnership, joint venture or other association between the parties. Danforth will be solely responsible for
payment of all charges and taxes arising from his or her relationship to the Company as a consultant. 

  

	14.	 Records. Upon termination of Danforth’s relationship with the Company, Danforth shall deliver to
the Company any property or Confidential Information of the Company relating to the Services which may be in its possession including products, project plans, materials, memoranda, notes, records, reports, laboratory notebooks, or other documents or
photocopies and any such information stored using electronic medium. 

  

	15.	 Notices. Any notice under this Agreement shall be in writing (except in the case of verbal
communications, emails and teleconferences updating either Party as to the status of work hereunder) and shall be deemed delivered upon personal delivery, one day after being sent via a reputable nationwide overnight courier service or two days
after deposit in the mail or on the next business day following transmittal via facsimile. Notices under this Agreement shall be sent to the following representatives of the Parties: 

If to the Company: 
  

			
	Title:	  	General Counsel
	Address:	  	101 Main Street, 14th Floor, Cambridge, MA, 02142

 If to Danforth: 
  

			
	Title:	  	Managing Director
	Address:	  	91 Middle Road
		  	Southborough, MA 01772

  

	16.	 Assignment and Successors. This Agreement may not be assigned by a Party without the consent of the
other which consent shall not be unreasonably withheld, except that each Party may assign this Agreement and the rights, obligations and interests of such Party, in whole or in part, to any of its Affiliates, to any purchaser of all or substantially
all of its assets or to any successor corporation resulting from any merger or consolidation of such Party with or into such corporation. 

  

	17.	 Force Majeure. Neither Party shall be liable for failure of or delay in performing obligations set forth
in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond the reasonable control of either Party. In the event of such force majeure, the Party affected
thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 

	18.	 Headings. The Section headings are intended for convenience of reference only and are not intended to be
a part of or to affect the meaning or interpretation of this Agreement. 

  

	19.	 Integration; Severability. This Agreement is the sole agreement with respect to the subject matter
hereof and shall supersede all other agreements and understandings between the Parties with respect to the same. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the Parties that the remainder of the Agreement shall not be affected. 

  

	20.	 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, excluding choice of law principles. The Parties agree that any action or proceeding arising out of or related in any way to this Agreement shall be brought solely in a Federal or State court of competent jurisdiction
sitting in the Commonwealth of Massachusetts. 

  

	21.	 Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original,
but all of which together will constitute one agreement. 

 If you are in agreement with the foregoing, please sign where indicated below,
whereupon this Agreement shall become effective as of the Effective Date. 
  

					
	DANFORTH ADVISORS, LLC	 		  	CHECKMATE PHARMACEUTICALS, INC.
			
	By:  /s/ Gregg
Beloff                                        
         	 		  	By:  /s/
Charles Abdalian                                      
  
			
	Print Name:  Gregg
Beloff                                        
	 		  	Print Name:  Charles Abdalian                             
 
			
	Title:  Managing
Director                                        
  	 		  	Title:  Chief Financial Officer                             
   
			
	Date:  June 6,
2019                                         
           	 		  	Date:  June 5, 2019                               
                  

 EXHIBIT A 

Description of Services and Schedule of Fees 

Danforth will perform mutually agreed to finance and accounting functions which are necessary to support the management and operations of the Company, certain
of which are set forth below. 
 Managing Director Services*; 
  

	 	•	 	 Participate in long-term strategic planning process 

 

	 	•	 	 Participate in financing activities, including additional capital raises (i.e. Series B) and/or debt and equity
restructurings 

  

	 	•	 	 Oversee the finance and accounting functions (if necessary) 

 

	 	•	 	 Board, Audit, Compensation, and Corporate Governance committee meeting preparation, support and attendance

  

	 	•	 	 Provide finance support for operational planning 

 

	 	•	 	 Assist with corporate and business development/licensing initiatives 

 

	 	•	 	 Perform financial modeling, planning and analysis a
Strategic opportunity assessment 

 VP of Finance Services: 

 

	 	•	 	 Review financial statements, and prepare reporting packages for investors, and the Board of Directors

  

	 	•	 	 Update and manage cap table 

 

	 	•	 	 Prepare for and manage financial statement audit (if necessary) 

 

	 	•	 	 Prepare detailed financial analyses, including forecasts, budgets, waterfall, etc. 

 

	 	•	 	 Analyze capital structure and cash/financing needs 

 

	 	•	 	 Account for and manage stock option grants, including oversight of the 409(a) valuation 

Note: Danforth provides a variety of other staffing needs and services (controller, accounting manager, financial planning and analysis etc.) which can be
included in a later amendment to this agreement or scope of work as agreed upon. Company has the right to review and approve any consultant prior to such consultant providing Consulting Services. 

Fees: 
  

			
	Managing Director: Jonathan Lieber	  	$400 / hour
	VP Finance: TBD	  	$235-$275/hourEX-10.1

 Exhibit 10.1 

Execution Copy 

EMPLOYMENT AGREEMENT 

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made by and between NEURONETICS, INC. (the
“Company”) and KEITH SULLIVAN (“Executive”). 
 WHEREAS, the Company desires to employ
Executive, and Executives wishes to be employed by the Company, on the terms and conditions set forth herein; and 
 WHEREAS, the parties
wish to enter into this Agreement to memorialize the terms of Executive’s continued employment by the Company. 
 NOW, THEREFORE, in
consideration of the foregoing and intending to be bound hereby, the parties agree as follows: 
 1. Duration of Agreement. This
Agreement is effective as of the date that Executive commences his employment with the Company (the “Effective Date”), and has no specific expiration date. Unless terminated by agreement of the parties, this Agreement will
govern Executive’s employment by the Company until that employment ceases. 
 2. Title; Duties. 

2.1. Executive will be employed as the Company’s President and Chief Executive Officer. Executive will devote his best efforts and
substantially all of his business time and services to the Company Group to perform such duties as may be customarily incident to his position and as may reasonably be assigned to him from time to time. Executive shall report to the Company’s
Board of Directors (the “Board”). Except as otherwise set forth in Section 2.2, Executive will not, in any capacity, engage in other business activities or perform services for any other individual, firm or corporation
without the prior written consent of the Board; provided, however, that without such consent, Executive may engage in charitable, non-profit and public service activities, so long as such
activities do not in any respect interfere or conflict with Executive’s performance of his duties and obligations to the Company Group; and provided further that Executive may serve on for-profit boards
of directors (other than the Board) only with the consent of the Board. 
 2.2. Executive agrees to reduce his current for-profit board service from three (3) companies to two (2) companies within six (6) months after the Effective Date. Executive and the Board will periodically discuss whether continued outside for-profit board service is consistent with the requirements of Section 2.1 as well as the policies of proxy advisory firms and institutional investors. Executive agrees to comply with any reasoned decision of
the Board with respect thereto. 
 2.3. The Board intends to appoint Executive to fill a newly created vacancy resulting from the increase of
the size of the Board from six members to seven members contemporaneously with or as promptly as practicable after the Effective Date. Thereafter, Executive’s election to serve as a continuing director on the Board shall be determined by the
Company’s stockholders. 
  

 3. Place of Performance. Executive will substantially perform his services hereunder
at the principal executive offices of the Company in Malvern, PA; provided, however, that Executive may be required to travel from time to time for business purposes. 

4. Compensation. 
 4.1.
Base Salary. Executive’s annual salary (the “Base Salary”) will be six hundred thousand dollars ($600,000), paid in accordance with the Company’s payroll practices as in effect from time to time. The Base Salary
will be reviewed annually beginning in the first quarter of 2021 by the Compensation Committee of the Company’s Board of Directors (the “Committee”). The Committee will make recommendations to the Board concerning, and
the non-executive Board members will determine, Base Salary in their respective discretion. 
 4.2.
Annual Bonus. Executive shall be eligible to receive an annual incentive bonus (the “Bonus”), with a target amount equal to 75% of his Base Salary, subject to annual review by the Committee. The Committee will make
recommendations to the Board concerning, and the non-executive Board members will determine, Executive’s Bonus target in their respective discretion. The actual Bonus payable with respect to a particular
fiscal year will be determined by the Board, after consulting with the Committee, based on the achievement of corporate and/or individual objectives established by the Board in consultation with the Committee and Executive. Notwithstanding the
foregoing, the Bonus payable for the Company’s 2020 fiscal year shall be no less than the target Bonus, determined on a pro rata basis based on the number of days Executive is employed by the Company during 2020. Any Bonus payable under this
paragraph will be paid during the calendar year immediately following the fiscal year in respect of which the bonus is payable and, except as otherwise provided in Section 5.1.1, will only be paid if Executive remains
continuously employed by the Company through the actual bonus payment date. 
 4.3. Equity Incentive Awards. 

4.3.1. Beginning in 2022, Executive shall be eligible to receive equity-based compensation commensurate with his position in connection with
any annual equity-based awards made to senior executives of the Company. Such awards shall be made in the sole discretion of the Committee and shall be subject to the terms and conditions set forth in the Company’s 2018 Equity Incentive Plan
(the “Plan”) (or other applicable plan) and award agreements, and in all cases shall be recommended by the Committee and determined by the non-executive Board members in their
respective discretion. 
 4.3.2. As an inducement to Executive’s employment with the Company, the Committee shall approve a grant of
two million (2,000,000) shares of the Company’s common stock (the “Sign-On Equity Grant”). The Sign-On Equity Grant will be made on the
Effective Date. Such Sign-On Equity Grant shall be structured as an inducement grant under Nasdaq Listing Rule 5635(c), but otherwise subject to all terms and conditions of the Plan and related agreements.

  
 -2- 

 4.3.3. The Sign-On Equity Grant shall be in the
form of: (i) restricted stock units representing five hundred thousand (500,000) shares of the Company’s common stock, vesting in four (4) annual installments on the anniversary of the grant date; (ii) non-qualified stock options
representing one million (1,000,000) shares of common stock with an exercise price equal to the closing price of the Company’s common stock on the grant date and with 25% vesting on the first anniversary of the grant date and the remaining 75%
vesting ratably over the following thirty-six (36) months; and (iii) performance stock units representing five hundred thousand (500,000) shares of the Company’s common stock vesting upon
attainment of the performance metrics set forth in the grant agreement, in each case of clauses (i) through (iii), subject to Executive’s continuous employment with the Company through the relevant date. 

4.4. Employee Benefits. During Executive’s employment, Executive will be eligible to participate in all employee benefit plans and
programs made available by the Company from time to time to its executives generally, subject to applicable plan terms and policies. The Company periodically reviews its benefits, policies, benefits providers and practices and may terminate, alter
or change them at its discretion from time to time. 
 4.5. Reimbursement of Expenses. Executive will be reimbursed by the Company for
all reasonable business expenses incurred by Executive in accordance with the Company’s customary expense reimbursement policies as in effect from time to time; provided, however, that in lieu of reimbursement for personal mileage
for travel by automobile, Executive shall receive a monthly stipend in the amount of one thousand two hundred dollars ($1,200) (grossed-up for applicable taxes). Notwithstanding anything herein to the
contrary, to the extent any expense, reimbursement or in-kind benefit provided to Executive constitutes a “deferral of compensation” within the meaning of Section 409A of the Internal Revenue
Code (the “Code”) (i) the amount of expenses eligible for reimbursement or in-kind benefits provided to Executive must be incurred during Executive’s term of employment;
(ii) the amount of expenses eligible for reimbursement or in-kind benefits provided to Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to Executive in any other calendar year, (iii) the reimbursements for expenses for which Executive is entitled to be reimbursed shall be made on or before the last day of the calendar
year following the calendar year in which the applicable expense is incurred and (iv) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other
benefit. 
 5. Termination. Executive’s employment with the Company may be terminated by the Company or Executive at any time and
for any reason. Upon any cessation of his employment with the Company, Executive will be entitled only to such compensation and benefits as described in this Section 5. Upon any cessation of his employment for any reason,
unless otherwise requested by the Company, Executive agrees to resign immediately from all officer and director positions he then holds with the Company Group. 

5.1. Termination without Cause or for Good Reason. If Executive’s employment by the Company ceases due to a termination by the
Company without Cause or a resignation by Executive for Good Reason, Executive will be entitled to: 
 5.1.1. payment of any annual bonus
otherwise payable (but for the cessation of Executive’s employment) with respect to a year ended prior to the cessation of Executive’s employment; 

  
 -3- 

 5.1.2. continuation of Executive’s Base Salary for a period equal to twelve
(12) months (“Severance Period”), payable in accordance with the Company’s standard payroll practices; 

5.1.3. payment of prorated Bonus for the current year based on the achievement of the performance criteria achieved through the termination
date, as determined by the Board after consultation with the Committee, paid in accordance with the Company’s standard payroll practices; and 

5.1.4. if Executive is eligible for COBRA benefits, waiver of the applicable premium otherwise payable for COBRA continuation coverage for
Executive (and, to the extent covered immediately prior to the date of such cessation, his eligible dependents) during the Severance Period. 
 Except as
otherwise provided in this Section 5.1, and except for payment of all (i) accrued and unpaid Base Salary through the date of such cessation, (ii) any expense reimbursements to be paid in accordance with the
Company policy and (iii) payments for any accrued but unused paid time off in accordance with the Company’s policies and applicable law, all compensation and benefits will cease at the time of such cessation and the Company Group will have
no further liability or obligation by reason of such cessation. The payments and benefits described in this Section 5.1 are in lieu of, and not in addition to, any other severance arrangement maintained by the Company
Group. Notwithstanding any provision of this Agreement, the payments and benefits described in Section 5.1 are conditioned on: (i) Executive’s execution and delivery to the Company and the expiration of all
applicable statutory revocation periods, by the 45th day following the effective date of his cessation of employment, of a general release of claims against the Company Group in a form reasonably prescribed by the Company (the
“Release”); and (b) Executive’s continued compliance with the Restrictive Covenants (as defined below). Subject to Section 5.4, the benefits described in Section 5.1 will
be paid or provided (or begin to be paid or provided) as soon as administratively practicable (or determinable in the case of the benefits described in Sections 5.1.1 and 5.1.3, if later) after the Release becomes irrevocable, provided that
if the 45 day period described above begins in one taxable year and ends in a second taxable year such payments or benefits shall not commence until the second taxable year. 

5.2. Termination Following a Change in Control. If Executive’s employment by the Company ceases due to a termination by the Company
without Cause or a resignation by Executive for Good Reason during the twelve (12) month period immediately following the occurrence of a Change in Control (as defined below), in addition to the benefits provided pursuant to
Section 5.1, the Severance Period shall be extended from twelve (12) months to eighteen (18) months and all outstanding unvested restricted stock, stock options and other equity incentives awarded to Executive by
the Company, including, without limitation, the Sign-On Equity Grant, will become immediately and automatically fully vested and exercisable (as applicable), subject to Executive’s execution and non-revocation of the Release. 

  
 -4- 

 5.3. Other Terminations. If Executive’s employment with the Company ceases for
any reason other than as described in Section 5.1 or Section 5.2 above (including but not limited to termination (i) by the Company for Cause, (ii) by Executive without Good Reason,
(iii) as a result of Executive’s retirement, (iv) as a result of Executive’s death or (v) as a result of Executive’s Disability, then the Company Group’s obligation to Executive will be limited solely to
(a) accrued and unpaid Base Salary through the date of such cessation, (b) any expense reimbursements to be paid in accordance with the Company policy and (c) payments for any accrued but unused paid time off in accordance with the
Company’s policies and applicable law. All compensation and benefits will cease at the time of such cessation and, except as otherwise provided by COBRA or this Section 5.3, the Company Group will have no further
liability or obligation by reason of such termination. The foregoing will not be construed to limit Executive’s right to payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding an
employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract. 
 5.4. Compliance
with Section 409A. If the termination giving rise to the payments described in Section 5.1 or Section 5.2 is not a “Separation from Service” within the
meaning of Treas. Reg. § 1.409A-1(h)(1) (or any successor provision), then the amounts otherwise payable pursuant to that section will instead be deferred without interest and will not be paid until
Executive experiences a Separation from Service. To the maximum extent permitted under Section 409A of the Code and its corresponding regulations, the cash severance benefits payable under this Agreement are intended to meet the requirements of
the short-term deferral exemption under Section 409A of the Code and the “separation pay exception” under Treas. Reg. §1.409A-1(b)(9)(iii). To the extent compliance with the requirements of
Treas. Reg. § 1.409A-3(i)(2) (or any successor provision) is necessary to avoid the application of an additional tax under Section 409A of the Internal Revenue Code to payments due to Executive upon
or following his Separation from Service, then notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy, agreement or arrangement), any such payments that are otherwise due within six months following
Executive’s Separation from Service (taking into account the preceding sentence of this paragraph) will be deferred without interest and paid to Executive in a lump sum immediately following that six month period. For purposes of the
application of Treas. Reg. § 1.409A-1(b)(4) (or any successor provision), each payment in a series of payments will be deemed a separate payment. 

5.5. PPACA. Notwithstanding anything in this Agreement to the contrary, the waiver in respect of COBRA premiums pursuant to
Section 5.1 shall cease to the extent required to avoid adverse consequences to the Company Group under the Patient Protection and Affordable Care Act of 2010 and regulations thereunder. 

5.6. Section 280G. If any payment or distribution by the Company to or for the benefit of Executive, whether paid or
payable or distributed or distributable pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any other agreement, policy, plan, program or arrangement or the lapse or termination of any restriction on or the vesting or
exercisability of any payment or benefit (each a “Payment”), would be subject to the excise tax imposed by Section 4999 of the Code (or any successor provision thereto) or to any similar tax imposed by state or local law
(such tax or taxes are hereafter collectively referred to as the “Excise Tax”), then the aggregate amount of Payments payable to Executive shall be reduced to the aggregate amount of Payments that may be made to Executive
without incurring an excise tax (the “Safe-Harbor Amount”) in accordance with the immediately following sentence; provided that such reduction shall only be imposed if the aggregate
after-tax value of the Payments retained by Executive (after giving effect to such reduction) is equal to or greater than 

  
 -5- 

 
the aggregate after-tax value (after giving effect to the Excise Tax) of the Payments to Executive without any such reduction. Any such reduction shall be
made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary, to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all
non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity derivative payments shall be reduced. 

5.7. Definitions. For purposes of this Agreement: 

5.7.1. “Cause” means Executive’s (a) conviction of, or the entry of a plea of guilty or no contest to, a
felony, any crime of moral turpitude or any other crime that materially adversely affects the Company Group’s operations, financial performance, reputation, or relationship with its customers, suppliers or employees; (b) chronic alcohol
abuse or abuse of controlled drugs; (c) a material breach of this Agreement or any duty owed to the Company Group; (d) dishonesty, including fraud, embezzlement, theft or other misuse of property with respect to the Company Group;
(e) refusal to perform the lawful and reasonable directives of the Board; (f) gross negligence or willful misconduct in the performance of duties (g) or breach of Executive’s restrictive covenants; or (h) a material
violation of any written policy of the Company Group, including, without limitation, policies relating to discrimination, harassment, fraternization and nepotism. 

5.7.2. “Change in Control” shall have the same meaning given it under the Plan. 

5.7.3. “Disability” means a condition entitling Executive to benefits under the Company’s long term disability
plan, policy or arrangement; provided, however, that if no such plan, policy or arrangement is then maintained by the Company and applicable to Executive, “Disability” will mean Executive’s inability to perform his
duties under this Agreement due to a mental or physical condition that can be expected to result in death or that can be expected to last (or has already lasted) for a continuous period of 90 days or more, or for 120 days in any 180 consecutive day
period. Termination as a result of a Disability will not be construed as a termination by the Company “without Cause.” 
 5.7.4.
“Good Reason” means any of the following, without Executive’s prior consent: (a) a material reduction in Base Salary or target Bonus opportunity (except for reductions proportionately applicable to all of the
Company’s executives); (b) a material diminution of Executive’s duties or responsibilities; or (c) a material breach of this Agreement by the Company. However, none of the foregoing events or conditions will constitute Good Reason
unless Executive provides the Company with written objection to the event or condition within thirty (30) days following the occurrence thereof, the Company does not reverse or otherwise cure the event or condition within thirty (30) days
of receiving that written objection, and Executive resigns Executive’s employment within thirty (30) days following the expiration of that cure period. 

6. Restrictive Covenants. To induce the Company to enter into this Agreement and in recognition of the compensation to be paid to
Executive pursuant to Sections 4 and 5 of this Agreement, Executive agrees to be bound by the provisions of this Section 6 (the “Restrictive Covenants”). The Restrictive Covenants will apply
without regard to whether any termination or cessation of Executive’s employment is initiated by the Company or Executive, and without regard to the reason for that termination or cessation. 

  
 -6- 

 6.1. Covenant Not To Solicit. Executive covenants that, during his employment by the
Company and for a period of twenty four (24) months following immediately thereafter (the “Restricted Period”), Executive shall not, directly or indirectly, for Executive’s own benefit or for the benefit of any
other Person, in any capacity (as a principal, shareholder, partner, member, investor, director, officer, agent, advisor, executive, consultant, contractor, employee, lender or otherwise): 

6.1.1. direct, induce, solicit, recruit or attempt to persuade any Person to terminate such Person’s employment or other relationship
with the Company Group or not to establish an employment or other relationship with the Company Group, whether or not such Person is or would be an employee, consultant, contractor, officer and/or director, whether or not such relationship is or
would be pursuant to a written or oral agreement and whether or not such relationship is for a specific period of time or is at-will; 

6.1.2. employ or establish a business relationship with (or attempt to employ or establish a business relationship with), or encourage or
assist any Person to employ or establish a business relationship with, any individual who was an employee, consultant, contractor, officer or director of the Company Group during the twelve month period preceding such termination; 

6.1.3. call upon, solicit, contact, or serve in any capacity any of the then-existing clients, Customers, vendors or suppliers of the Company
Group, any clients, Customers, vendors or suppliers that have had a relationship with the Company Group during the twelve (12) months preceding the Termination Date, or any potential clients, Potential Customers, vendors or suppliers that were
solicited by the Company Group during the twelve (12) months preceding the Termination Date for the purpose of engaging in a Competing Business or in any manner that could adversely affect alter or change the relationship (contractual or
otherwise) which such clients, Customers, Potential Customers, vendors or suppliers have with the Company Group; 
 6.1.4. (a) direct or
engage in any act or omission that could otherwise disrupt, damage, impair, or interfere with the business of the Company Group (or attempt to do the same) whether by way of interfering with or disrupting the relationship of the Company Group with
employees, customers, agents, representatives, clients, Customers, Potential Customers, vendors, suppliers consultants or contractor of the Company Group, or (b) otherwise induce or attempt to induce any such Person to cease doing business,
reduce or otherwise limit its business with the Company Group; or 
 6.1.5. solicit business from any Customer or Prospective Customer, or
do business with any Customer or Prospective Customer of the Company Group, involving the Business. 
 6.2.
Non-Competition. During Executive’s service with the Company Group and for the Restricted Period, Executive shall not, directly or indirectly, for Executive’s own benefit or for the benefit of
any other Person, in any capacity (as a principal, shareholder, partner, member, investor, director, officer, agent, advisor, executive, consultant, contractor, 

  
 -7- 

 
employee, lender or otherwise), engage or participate in, or be financially interested in, any Person involved in a Competing Business anywhere in the United States or any other country or region
in which the Company Group is then selling its products and services, is planning to sell its products and services or is planning to apply for, or has applied for, regulatory approval to sell its products and services, including but not limited to,
those Persons set forth on Attachment A (provided, however, that nothing contained in this Section 6.2 shall prevent Executive from holding for passive investment of less than two percent (2%) of any class of
equity securities of a company whose securities are publicly traded on a national securities exchange or in a national market system). 

6.3. Confidentiality. Executive recognizes and acknowledges that the Proprietary Information (as defined in below) is a valuable,
special and unique asset of the business of the Company Group. As a result, both during the Term and for the ten (10) year period thereafter, Executive will not, without the prior written consent of the Company, for any reason divulge to any third-party or use for his own benefit, or for any purpose other than the exclusive benefit of the Company Group, any Proprietary Information, provided, however, that during the Term and at all times
thereafter, Executive will not, without the prior written consent of the Company, for any reason divulge to any third-party or use for his own benefit, or for any purpose other than the exclusive benefit of
the Company Group, any trade secrets. Notwithstanding the foregoing, nothing in this Agreement prohibits Executive from initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential
information to, reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment
Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General (collectively, the
“Regulators”), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. In connection with any such activity, Executive must identify any information that
is confidential and ask the Regulator for confidential treatment of such information. Despite the foregoing, Executive is not permitted to reveal to any other Person, including any governmental, law enforcement, or regulatory authority, information
employee came to learn during the course of Executive’s employment with the Company that is protected from disclosure by any applicable privilege, including but not limited to the attorney-client privilege, attorney work product doctrine and/or
other applicable legal privileges. The Company Group does not waive any applicable privileges or the right to continue to protect its privileged attorney-client information, attorney work product, and other privileged information. Notwithstanding
any other provisions of this Agreement, pursuant to 18 USC Section 1833(b), Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of the Company Group’s trade secret that is
made: (a) confidentially to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (b) in a complaint or
other document filed in a lawsuit or other proceeding, if such filing is made under seal. If Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose a trade secret to
Executive’s attorney and use the trade secret information in related court proceedings, provided that Executive files any document containing the trade secret information under seal and does not disclose the trade secret, except pursuant to
court order. Executive agrees that he will not, while employed by the 

  
 -8- 

 
Company or engaged as a consultant and/or director of the Company Group, improperly use or disclose any proprietary information or trade secrets of any former or concurrent employer or other
Person, if any, with whom Executive has an agreement or duty to keep such information or secrets confidential, if any, and that Executive will not use, disclose or bring onto the premises of the Company Group any unpublished document or proprietary
information belonging to any such employer or Person unless consented to in writing by such employer or Person. Executive recognizes that the Company Group has received and in the future will receive from third parties (including customers of the
Company Group) their confidential or proprietary information subject to a duty on the Company Group’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. Executive agrees to hold all such
confidential or proprietary information in the strictest confidence and not to disclose it to any Person or to use it except as necessary in carrying out Executive’s work for the Company Group, consistent with the Company Group’s agreement
with such other Person. 
 6.4. Property of the Company Group. 

6.4.1. Proprietary Information. All right, title and interest in and to Proprietary Information will be and remain the sole and
exclusive property of the Company Group. Executive will not remove from the Company Group’s offices or premises any documents, records, notebooks, files, correspondence, reports, memoranda or similar materials of or containing Proprietary
Information, or other materials or property of any kind belonging to the Company Group unless necessary or appropriate in the performance of his duties to the Company Group. If Executive removes such materials or property in the performance of his
duties, he will return such materials or property promptly after the removal has served its purpose. Executive will not make, retain, remove and/or distribute any copies of any such materials or property, or divulge to any third person the nature of
and/or contents of such materials or property, except to the extent necessary to satisfy contractual obligations of the Company Group, to perform his duties on behalf of the Company Group or pursuant to the exceptions set forth in
Section 6.3. Upon termination of Executive’s employment with the Company, he will leave with the Company Group or promptly return to the Company Group all originals and copies of such materials or property then in his
possession. 
 6.4.2. Intellectual Property. 

(a) Executive has attached hereto, as Attachment B, a list describing all inventions, original works of authorship, developments,
improvements, and trade secrets which were made by Executive prior to becoming an employee, consultant, officer and/or director of the Company (collectively referred to as “Prior Inventions), which are owned by Executive alone or
jointly with others, which relate to the Company Group’s business, proposed business, products or research and development, and which are not assigned to the Company Group hereunder; or, if no such list is attached, Executive represents that
there are no such Prior Inventions. If in the course of Executive’s service with the Company Group, Executive incorporates into a Company Group product, process or machine a Prior Invention owned by Executive or in which Executive has an
interest, the Company, or its designee, is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide, assignable, transferable, and sub-licenseable license to make, have
made, modify, use and sell such Prior Invention as part of or in connection with such product, process or machine. 

  
 -9- 

 (b) Executive agrees that he will promptly make full written disclosure to the Company,
will hold in trust for the sole right and benefit of the Company, and hereby assigns to the Company, or its designee, all Executive’s right, title, and interest in and to any and all inventions, original works of authorship, developments,
concepts, improvements or any trade secrets which relate in any manner to the Company Group’s business or proposed business, whether or not patentable or registrable under patent, copyright or similar laws, which Executive may solely or jointly
conceive or develop or reduce to practice (or may have conceived or developed or reduced to practice) or cause (or may have caused) to be conceived or developed or reduced to practice, at any time prior to the date of this Agreement until Executive
is no longer an employee, consultant, officer and/or director of the Company (collectively referred to as “Inventions”), including any and all intellectual property rights inherent in the Inventions and appurtenant thereto
including, without limitation, all patent rights, copyrights, trademark rights and trade secret rights (collectively referred to as “Intellectual Property Rights”). Executive further acknowledges that all original works of
authorship which are made by Executive (solely or jointly with others) within the scope of Executive’s service or duties as an employee, consultant, officer and/or director and which are protectable by copyright are “works made for
hire”, as that term is defined in the United States Copyright Act. 
 (c) Executive agrees to keep and maintain adequate and current
records of all Inventions. The records will be in the form of notes, sketches, drawings, and any other format that may be specified by the Company. The records will be available to the Company at all times, and the Company, or its designee, shall
retain all right, title, and interest in and to the same. 
 (d) Executive agrees to assist the Company, or its designee, at the
Company’s expense, in every proper way to secure the Company Group’s rights in the Inventions and any Intellectual Property Rights related thereto in any and all countries, including the disclosure to the Company of all pertinent
information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary in order to apply for and obtain such rights and in order to assign and
convey to the Company, or its designee, the sole and exclusive right, title and interest in and to such Inventions and any Intellectual Property Rights relating thereto. Executive further agrees that Executive’s obligation to execute or cause
to be executed, when it is in Executive’s power to do so, any such instrument or papers shall continue after the termination of this Agreement. If the Company is unable because of Executive’s mental or physical incapacity or for any other
reason to secure Executive’s signature to apply for or to pursue any application for any United States or foreign Intellectual Property Right covering Inventions assigned to the Company, or its designee, as above, then Executive hereby
irrevocably designates and appoints the Company and its duly authorized officers and agents as Executive’s agent and attorney in fact, to act for and in Executive’s behalf and stead to execute and file any such applications and to do all
other lawfully permitted acts to further the prosecution and issuance of letters patent, or copyright, trademark or other registrations thereon with the same legal force and effect as if executed by Executive. 

6.5. Returning the Company Group Documents and Property. Executive agrees that, upon termination of Executive’s service with the
Company, for any reason, Executive will deliver to the Company, or its designee, and will not keep in Executive’s possession or deliver to 

  
 -10- 

 
anyone else, any and all records, data, notes, reports, information, proposals, lists, correspondence, emails, specifications, drawings, blueprints, sketches, materials, other documents, or
reproductions or copies (including but not limited to on computer discs or drives) of any aforementioned items either developed by Executive pursuant to Executive’s service with the Company or otherwise relating to the business of the Company
Group, retaining neither copies nor excerpts thereof. Executive also agrees that, at such time, or earlier upon request, Executive will deliver to the Company, or its designee, all the Company Group property in Executive’s possession, including
cell phones, computers, computer discs, drives and other equipment or devices, and that if Executive fails to do so the Company may withhold from Executive’s compensation the replacement cost of the Company Group property Executive has not
returned. 
 6.6. Non-Disparagement. Executive acknowledges and agrees that Executive will not
while employed by the Company or engaged as a consultant and/or director of the Company and for the ten (10) year period following the end of such service with the Company, whether in writing or orally, malign, denigrate or disparage the
Company Group or any of their respective predecessors or successors, or any of the current or former directors, officers, employees, shareholders, partners, members, agents or representatives of any of the foregoing, with respect to any of their
respective past or present activities, or otherwise publish (whether in writing or orally) statements that tend to portray any of the aforementioned parties in an unfavorable light. Disclosure of information Executive is required to disclose
pursuant to any applicable law, court order, subpoena, compulsory process of law or governmental decree shall not constitute a violation or breach of this Section 6.6, provided that Executive delivers written notice of such
required disclosure to the Company or its designee promptly before making such disclosure if such notice is not prohibited by applicable law, court order, subpoena, compulsory process of law or governmental decree. 

6.7. Relatives, Affiliates, Etc. Executive acknowledges and agree that Executive will not hire or otherwise engage to provide products
or services to the Company Group (as an employee, consultant, supplier, vendor, or otherwise) any Person that is Executive’s Affiliate or any Person that is Executive’s familial relative by marriage or by birth (including adoption) without
disclosure to and the written consent of the Board. 
 6.8. Definitions. For purposes of this Agreement: 

6.8.1. “Affiliate” means, with respect to any specified Person, any other Person that directly or indirectly, through
one or more intermediaries, Controls, is Controlled by, or is under common Control with, such specified Person, provided that, in any event, any business in which the Company has any direct ownership interest shall be treated as an Affiliate of the
Company. 
 6.8.2. “Company Group” means, collectively and individually, the Company and each of its Affiliates.

 6.8.3. “Competing Business” means any Person engaged in the development, manufacture and marketing of medical
devices indicated for treatment of depression, or any other indications developed, being developed or being considered for development by the Company. 

  
 -11- 

 6.8.4. “Control” (including, with correlative meanings, the terms
“Controlled by” and “under common Control with”), as used with respect to any Person, means the direct or indirect possession of the power to direct or cause the direction of the management or policies of such Person, whether
through the ownership of voting securities, by contract or otherwise. 
 6.8.5. “Customer” shall mean those Persons
for whom or which the Company Group performed services or to whom or which the Company Group sold or licensed its products, during the twelve (12) months preceding the cessation of Executive’s employment with the Company for any reason.

 6.8.6. “Intellectual Property” means (a) all inventions (whether patentable or un-patentable and whether or not reduced to practice), all improvements thereto, and all patents and patent applications claiming such inventions, (b) all trademarks, service marks, trade dress, logos, trade
names, fictitious names, brand names, brand marks and corporate names, together with all translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications, registrations, and
renewals in connection therewith, (c) all copyrightable works, all copyrights, and all applications, registrations, and renewals in connection therewith, (d) all mask works and all applications, registrations, and renewals in connection
therewith, (e) all trade secrets (including research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, methodologies, technical data, designs,
drawings and specifications), (f) all computer software (including data, source and object codes and related documentation), (g) all other proprietary rights, (h) all copies and tangible embodiments thereof (in whatever form or medium), or
(i) similar intangible personal property which have been or are developed or created in whole or in part by Executive (a) at any time and at any place while Executive is employed by the Company and which, in the case of any or all of the
foregoing, are related to and used in connection with the business of the Company Group, or (b) as a result of tasks assigned to Executive by the Company Group. 

6.8.7. “Person” means any individual, firm, corporation, partnership, limited liability company, trust, joint venture,
association, governmental entity, unincorporated entity or other entity. 
 6.8.8. “Proprietary Information” means
any and all the Company Group proprietary or confidential information, technical data, trade secrets or know-how, including, but not limited to, research, product plans and developments, prototypes, products,
services, client lists and clients, prospective clients and contacts, proposals, client purchasing practices, prices and pricing methodology, cost information, terms and conditions of business relationships with clients, client research and other
needs, markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, distribution and sales methods and systems, sales and profit figures, finances, personnel information including, but not limited to,
information regarding compensation, skills and duties, as well as reports and other business information that Executive learns of, obtain, or that is disclosed to Executive relating to the Company Group at any time prior to or during the course of
Executive’s service to the Company, either directly or indirectly, in writing, orally or by review or inspection of documents or other tangible property. Failure by the Company Group to mark any of the Proprietary Information as confidential or
proprietary shall not affect its status as Proprietary Information. 

  
 -12- 

 6.8.9. “Prospective Customer” shall mean Persons whose business was
solicited by the Company Group during the twelve (12) months preceding the date on which Executive’s employment with the Company ceases for any reason. 

6.9. Acknowledgements. Executive acknowledges that the Restrictive Covenants are reasonable and necessary to protect the legitimate
interests of the Company Group, that the duration and geographic scope of the Restrictive Covenants are reasonable given the nature of this Agreement and the position Executive holds within the Company, and that the Company would not enter into this
Agreement or otherwise employ Executive unless Executive agrees to be bound by the Restrictive Covenants set forth in this Section 6. 

6.10. Remedies and Enforcement Upon Breach. 

6.10.1. Specific Enforcement. Executive acknowledges that any breach by him, willfully or otherwise, of the Restrictive Covenants will
cause continuing and irreparable injury to the Company Group for which monetary damages would not be an adequate remedy. Executive shall not, in any action or proceeding to enforce any of the provisions of this Agreement, assert the claim or defense
that such an adequate remedy at law exists. In the event of any such breach or threatened breach by Executive of any of the Restrictive Covenants, the Company Group, as applicable, shall be entitled to injunctive or other similar equitable relief in
any court, without any requirement that a bond or other security be posted, and this Agreement shall not in any way limit remedies of law or in equity otherwise available to the Company Group. 

6.10.2. Economic Remedies. Executive acknowledges and agree that if Executive breaches any of the provisions of this Agreement, the
Company will have the right and remedy to require Executive to account for and pay over to the Company or its designee, all compensation, profits, monies, accruals, increments or other benefits Executive derives or receives as a result of such
breach. This right and remedy will be in addition to, and not in lieu of, any other rights and remedies available to the Company Group under law or in equity. 

6.10.3. Judicial Modification. If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable
because of the duration or geographical scope of such provision, such court shall have the power to modify such provision and, in its modified form, such provision shall then be enforceable. 

6.10.4. Enforceability. If any court holds the Restrictive Covenants unenforceable by reason of their breadth or scope or otherwise, it
is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company Group to the relief provided above in the courts of any other jurisdiction within the geographic scope of such Restrictive
Covenants. 
 6.10.5. Disclosure of Restrictive Covenants. Executive agrees to disclose the existence and terms of the Restrictive
Covenants to any employer that Executive may work for during the Restricted Period. 

  
 -13- 

 6.10.6. Extension of Restricted Period. If Executive breaches
Section 6.1 in any respect, the restrictions contained in that section will be extended for a period equal to the period that Executive was in breach. 

7. Miscellaneous. 
 7.1.
Other Agreements. Executive represents and warrants to the Company that there are no restrictions, agreements or understandings whatsoever to which he is a party that would prevent or make unlawful his execution of this Agreement, that would
be inconsistent or in conflict with this Agreement or Executive’s obligations hereunder, or that would otherwise prevent, limit or impair the performance by Executive of his duties under this Agreement. 

7.2. Cooperation. Executive further agrees that she will cooperate fully with the Company and its counsel with respect to any matter
(including litigation, investigations, or governmental proceedings) in which Executive was in any way involved during his employment with the Company. Executive shall render such cooperation in a timely manner on reasonable notice from the Company.
The Company shall reimburse Executive any reasonable expenses incurred in rendering such cooperation. 
 7.3. Successors and Assigns.
The Company may assign this Agreement to any successor to its assets and business by means of liquidation, dissolution, sale of assets or otherwise. The duties of Executive hereunder are personal to Executive and may not be assigned by him. 

7.3.1. Governing Law and Enforcement. This Agreement will be governed by and construed in accordance with the laws of the Commonwealth
of Pennsylvania, without regard to the principles of conflicts of laws. Any legal proceeding arising out of or relating to this Agreement will be subject to mediation followed by binding arbitration in Chester County, PA, provided, however,
that any dispute involving the Restrictive Covenants of Section 6 may be instituted in a state or federal court in the Commonwealth of Pennsylvania, and Executive and the Company hereby consent to the personal and exclusive
jurisdiction of such court(s) and hereby waive any objection(s) that they may have to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum. 

7.4. Waivers. The waiver by either party of any right hereunder or of any breach by the other party will not be deemed a waiver of any
other right hereunder or of any other breach by the other party. No waiver will be deemed to have occurred unless set forth in a writing. No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only as
to the specific term or condition waived. 
 7.5. Severability. Whenever possible, each provision of this Agreement will be
interpreted in such manner as to be effective and valid under applicable law. However, if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect
any other provision, and this Agreement will be reformed, construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained. 

  
 -14- 

 7.6. Survival. This Agreement will survive the cessation of Executive’s
employment to the extent necessary to fulfill the purposes and intent the Agreement. 
 7.7. Notices. Any notice or communication
required or permitted under this Agreement will be made in writing and (a) sent by overnight courier, (b) mailed by overnight U.S. express mail, return receipt requested, (c) sent by telecopier, or (d) sent by email. Any notice
or communication to Executive will be sent to the address contained in his personnel file. Any notice or communication to the Company will be sent to the Company’s principal executive offices, to the attention of its General Counsel.
Notwithstanding the foregoing, either party may change the address for notices or communications hereunder by providing written notice to the other in the manner specified in this paragraph. 

7.8. Entire Agreement; Amendments. This Agreement contains the entire agreement and understanding of the parties hereto relating to the
subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature relating to that subject matter (including, without limitation, the employment term sheet). This Agreement may
not be changed or modified, except by an agreement in writing signed by each of the parties hereto. 
 7.9. Withholding. All payments
(or transfers of property) to Executive will be subject to tax withholding to the extent required by applicable law. 
 7.10. Section
Headings. The headings of sections and paragraphs of this Agreement are inserted for convenience only and will not in any way affect the meaning or construction of any provision of this Agreement. 

7.11. Counterparts; Facsimile. This Agreement may be executed in multiple counterparts (including by facsimile signature), each of which
will be deemed to be an original, but all of which together will constitute but one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered
shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 <remainder of page intentionally
left blank; signature page follows> 
  

  
 -15- 

 IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly
authorized officer, and Executive has executed this Agreement, on the date(s) indicated below. 
  

			
	NEURONETICS, INC.
		
	By:	 	 /s/ W. Andrew Macan

	Name: W. Andrew Macan
	Title: Office of the President, SVP & GC
	Date: July 14, 2020
	
	KEITH SULLIVAN
	
	 /s/ Keith J. Sullivan

	Date: July 14, 2020

 Signature Page to Employment Agreement 

 Attachments to Employment Agreement 

Omitted pursuant to Regulation S-K Item 601(a)(5) 

1. Attachment A - Competitors 
 2. Attachment B - Prior
Inventions

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]